Androgen deprivation therapy is often prescribed as a prostate cancer treatment for low-risk prostate cancer patients and has already come under scrutiny for causing increased risk of cardiovascular disease and other heart conditions.
Despite the seemingly alarming findings, the absolute risk for colorectal cancer is no more than 2.5 percent over a five-year period.
Read the news release about androgen deprivation therapy and CRC.
Read other coverage about colorectal cancer:
– Virtual colonoscopy a Possibility for Increased Patient Comfort
– AGA: Testing Between Colonoscopies Can Help Patients With High Risk of CRC
– CDC: 50% of CRC Cases Are Detected in Late Stages
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.